RJA
REGN icon

Raymond James & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Raymond James & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,400
Closed -$256K – 3643
2020
Q1 		$256K Buy
+2,400
New +$990K ﹤0.01% 2869

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Raymond James & Associates's REGN Position: Q3 2024 in Review

Raymond James & Associates increased its Regeneron Pharmaceuticals (REGN) stake by 10% in Q3 2024, buying an estimated $8.66M and bringing the position to 82,006 shares worth $86.2M. The position accounts for 0.05% of the portfolio, ranked #305.

Raymond James & Associates first reported a position in REGN in Q2 2015 and has held it in 38 quarters since. 1,389 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

  • Raymond James & Associates held 82,006 shares of Regeneron Pharmaceuticals worth $86.2M as of Q3 2024.
  • Raymond James & Associates bought 7,778 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $8.66M.
  • Regeneron Pharmaceuticals made up 0.05% of Raymond James & Associates's portfolio in Q3 2024, its #305 holding.
  • Raymond James & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 38 quarters since.
  • 1,389 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.